scispace - formally typeset
F

Frances E. Jensen

Researcher at University of Pennsylvania

Publications -  152
Citations -  15619

Frances E. Jensen is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Epilepsy & AMPA receptor. The author has an hindex of 63, co-authored 147 publications receiving 14290 citations. Previous affiliations of Frances E. Jensen include Boston Children's Hospital & Children's Medical Center of Dallas.

Papers
More filters
Journal ArticleDOI

Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation.

TL;DR: The results demonstrate that the new series sample method combined with three- dimensional reconstruction reveals quantitative changes in the frequency and structure of spines and synapses that are not discernable by other methods and are likely to have dramatic effects on synaptic physiology and plasticity.
Journal ArticleDOI

Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway

TL;DR: A mechanistic link among innate immunity, TLRs, and neurodegeneration is demonstrated and microglia is identified as the major lipopolysaccharide-responsive cell in the CNS.
Journal ArticleDOI

NKCC1 transporter facilitates seizures in the developing brain

TL;DR: Evidence that NKCC1 facilitates seizures in the developing brain is provided and indications that bumetanide should be useful in the treatment of neonatal seizures are indicated.
Journal ArticleDOI

The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS

TL;DR: The data provide a general mechanistic link between (1) lipopolysaccharide and similar microbial molecular motifs and (2) injury to oligodendrocytes and myelin as occurs in periventricular leukomalacia and multiple sclerosis.
Journal ArticleDOI

Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

TL;DR: Low micromolar concentrations of memantine, levels known to be tolerated by patients receiving the drug for the treatment of Parkinson's disease, prevent NMDA receptor-mediated neurotoxicity in cultures of rat cortical and retinal ganglion cell neurons; memantine also appears to be both safe and effective in a rat stroke model, suggesting that memantine has considerable therapeutic potential for the myriad of clinical entities associated with NMda receptor- mediated neurotoxicity.